United Kingdom

Engitix secures €21M to push ECM-Targeted Cancer and Fibrosis Pipeline Forward
London-based biotech company Engitix has raised €21 million ($25 million) in a Series A extension to advance its work on therapies targeting the extracellular matrix (ECM) in cancer and fibrotic diseases.

The best Articles in our Network